Biosimilar Remicade in Europe: implications
This article was originally published in Scrip
Executive Summary
Partners Hospira and Celltrion got lucky in garnering a positive recommendation in Europe for their biosimilar version of Johnson & Johnson/Merck's monoclonal antibody Remicade (infliximab) not just for rheumatoid arthritis, the indication in which they had clinical data showing similarity to Remicade, but also for other indications.